Sign in
Taking people in United StatesPhase 2

MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder

Key facts

Who runs it
Patricia Suppes
Where
Palo Alto, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
10 Feb 2025
Expected to end
Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • MDMA
  • Cognitive Processing Therapy
  • MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)
Record updated
31 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Are at least 18 years at the time of signing the informed consent
  • Are a U.S Military Veteran
  • Are receiving services from VA Palo Alto Healthcare System, VA San Francisco Healthcare System, or VA NorCal Healthcare System
  • Are fluent in speaking and reading in English
  • Agree to have study visits audio and/or video recorded
  • If assigned to MDMA-aCPT, able to identify appropriate support person(s) to stay with the participant on the evenings of the MDMA sessions
  • Meet DSM-5 criteria for PTSD with a symptom duration of at least 6 months
  • Have severe PTSD symptoms in the last month
  • Body weight of at least 48 kilograms (kg)
  • Is not pregnant, planning to get pregnant, or breastfeeding
  • Capable of giving signed informed consent

Who cannot take part

  • Have a history of any medical condition that could make receiving a sympathomimetic drug harmful
  • Have received Electroconvulsive Therapy (ECT), ketamine-assisted therapy, or used ketamine within 12 weeks of enrollment
  • Unable or unwilling to stop or safely taper off prohibited medications
  • Have current unstable medical illness
  • Moderate or severe alcohol or cannabis use disorder within the last 12 months
  • Active illicit drug (other than cannabis) or prescription drug substance use disorder at any severity within the last 12 months
  • Personal history of primary psychotic disorder, type I bipolar disorder, severe personality disorder, eating disorder with compensatory behaviors, or depressive disorder with psychotic features
  • Have cardiac conditions, including uncontrolled hypertension, prolonged QTc interval, and other cardiac conditions
  • Participants are excluded from the study if any of the following criteria apply:
  • Have current serious suicide risk
  • Have used MDMA (ecstasy) ever
  • Currently enrolled in any clinical study
  • Lack social support, or lack a stable living situation

This trial is currently available in United States.

  • VA Palo Alto Health Care System / Stanford UniversityPalo Alto, United StatesContact: Anna DonnellyTaking people

About the trial

What the trial wants to find out

In partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University, this study aims to evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) in the treatment of posttraumatic stress disorder (PTSD). Through a randomized comparison of MDMA-aCPT versus Cognitive Processing Therapy (CPT), a VA gold standard treatment for PTSD, the proposed study will set the stage for understanding the potential use and application of MDMA-aCPT for PTSD within the VA system.

The 2 groups in the trial

  • MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)Treatment being tested

    This arm consists of 8-15 virtual CPT sessions (average of 12), one 90-minute, non-drug Preparatory Session, three Experimental Sessions with MDMA (\~8 hours), and three 90-minute, non-drug Integration Sessions, occurring over a 9-15-week Treatment Period. Standardized homework is assigned at each CPT session to promote the practice of the skills taught in the session. Participants will receive 80mg MDMA HCl for the first Experimental Session and will have the option of a supplemental dose of 40mg MDMA HCI 1.5-2 hours after the initial dose. For the second and third Experimental Sessions, participants will receive either 80mg or 120mg MDMA HCl as the initial dose, and an optional supplemental dose of 40mg or 60mg MDMA HCl 1.5-2 hours after the initial dose. Participants interested in receiving CPT treatment alone after study completion will have the option to be referred to their local VA PTSD Clinical Team for services 6 months after all study visits are completed.

    Treatment: MDMA and MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)

  • Cognitive processing therapyTreatment being tested

    This arm consists of 8-15 virtual CPT treatment sessions lasting approximately 1-1.5 hours, occurring over a \~12-16-week Treatment Period. These sessions will take place approximately one week apart. Standardized homework is assigned at each session to promote the practice of the skills taught in the session. Participants will have the option to crossover to the MDMA-aCPT arm 6 months after all study visits are completed.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Trial to Compare MDMA-assisted Cognitive Processing Therapy (aCPT) Versus a VA Standard-of-care CPT for the Treatment of Severe Posttraumatic Stress Disorder Among Veterans
Record updated
31 July 2025